Under the terms with TEVA, Allergan retains the branded pharma business and medical aesthetic business, as well as its biosimilars development programs, including its collaboration with Amgen Inc, inherited in the 2012 merger of Actavis with Watson Pharmaceuticals) (Article, BioWorld, AUG 3, 2016, View Source [SID1234516258]).
President and CEO Brent Saunders said biosimilars remain a strategic fit for the company, adding that "we made substantial investments over the years that will pay out" in the future, both in terms of the Amgen collaboration and Allergan’s internal biosimilars programs

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!